Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Dtxsid10151274
Molecular Weight | 5832 g/mol |
---|---|
Molecular Formula | C256H387N65O79S6 |
Hydrogen Bond Donor Count | 86 |
Hydrogen Bond Acceptor Count | 91 |
Rotatable Bond Count | 188 |
Exact Mass | 5829.6654893 g/mol |
Monoisotopic Mass | 5827.6587796 g/mol |
Topological Polar Surface Area | 2350 Ų |
Heavy Atom Count | 406 |
Formal Charge | 0 |
Complexity | 13000 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 52 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Novolog |
PubMed Health | Insulin Aspart Protamine/Insulin Aspart (Injection) |
Drug Classes | Antidiabetic |
Drug Label | NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is a human insulin analog suspension containing 70% insulin aspart protamine crystals and 30% soluble insulin aspart. NovoLog Mix 70/30 is a b... |
Active Ingredient | Insulin aspart recombinant |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 1000 units/10ml (100 units/ml) |
Market Status | Prescription |
Company | Novo Nordisk |
2 of 2 | |
---|---|
Drug Name | Novolog |
PubMed Health | Insulin Aspart Protamine/Insulin Aspart (Injection) |
Drug Classes | Antidiabetic |
Drug Label | NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is a human insulin analog suspension containing 70% insulin aspart protamine crystals and 30% soluble insulin aspart. NovoLog Mix 70/30 is a b... |
Active Ingredient | Insulin aspart recombinant |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 1000 units/10ml (100 units/ml) |
Market Status | Prescription |
Company | Novo Nordisk |
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 1,567
2019 Revenue in Millions : 1,559
Growth (%) : 1
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 225
2019 Revenue in Millions : 202
Growth (%) : 11
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 2,753
2019 Revenue in Millions : 2,937
Growth (%) : -6
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 210
2019 Revenue in Millions : 162
Growth (%) : 30
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 261
2020 Revenue in Millions : 207
Growth (%) : 33
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 1,447
2020 Revenue in Millions : 1,541
Growth (%) : -1
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 266
2020 Revenue in Millions : 222
Growth (%) : 26
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 2,429
2020 Revenue in Millions : 2,708
Growth (%) : -6
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 1,119
2021 Revenue in Millions : 1,447
Growth (%) : -23
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 292
2021 Revenue in Millions : 266
Growth (%) : 10
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?